The neoadjuvant model is still the future for drug development in breast cancer

Clinical Cancer Research

Volumn 21, Issue 13, 2015, Pages 2911-2915

  De Michele, Angela ^a   Yee, Douglas ^b   Berry, Donald A ^c   Albain, Kathy S ^d   Benz, Christopher C ^e   Boughey, Judy ^f   Buxton, Meredith ^g   Chia, Stephen K ^h   Chien, Amy J ^g   Chui, Stephen Y ⁱ   Clark, Amy ^a   Edmiston, Kirsten ^j   Elias, Anthony D ^k   Forero Torres, Andres ^l   Haddad, Tufia C ^f   Haley, Barbara ^m   Haluska, Paul ^f   Hylton, Nola M ^g   Isaacs, Claudine ⁿ   Kaplan, Henry ^o   Korde, Larissa ^p   Leyland Jones, Brian ^q   Liu, Minetta C ^f   Melisko, Michelle ^g   Minton, Susan E ^r   Moulder, Stacy L ^c   Nanda, Rita ^s   Olopade, Olufunmilayo I ^s   Paoloni, Melissa ^t   Park, John W ^g   Parker, Barbara A ^u   Perlmutter, Jane ^v   Petricoin, Emanuel F ^w   Rugo, Hope ^g   Symmans, Fraser ^c   Tripathy, Debasish ^x   Van't Veer, Laura J ^g   Viscusi, Rebecca K ^y   Wallace, Anne ^u   Wolf, Denise ^g   Yau, Christina ^e   Esserman, Laura J ^g   more..

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d LOYOLA UNIVERSITY CHICAGO   (United States)

^e BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

^f MAYO CLINIC   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h BRITISH COLUMBIA CANCER AGENCY   (Canada)

ⁱ OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^j INOVA FAIRFAX HOSPITAL   (United States)

^k UNIVERSITY OF COLORADO   (United States)

^l UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^m UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

ⁿ GEORGETOWN UNIVERSITY   (United States)

^o SWEDISH MEDICAL CENTER   (United States)

^p UNIVERSITY OF WASHINGTON   (United States)

^q EMORY UNIVERSITY   (United States)

^r H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^s UNIVERSITY OF CHICAGO   (United States)

^t Quantum Leap Healthcare Collaborative   (United States)

^u UNIVERSITY OF CALIFORNIA   (United States)

^v Gemini Group   (United States)

^w GEORGE MASON UNIVERSITY   (United States)

^x UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^y UNIVERSITY OF ARIZONA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMATINIB; LAPATINIB; NERATINIB; PACLITAXEL; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DRUG APPROVAL; EVENT FREE SURVIVAL; FOLLOW UP; HUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; REGISTRATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; BREAST NEOPLASMS; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; FEMALE; NEOADJUVANT THERAPY;

BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; FEMALE; HUMANS; NEOADJUVANT THERAPY; TREATMENT OUTCOME;

EID: 84941678069     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-1760     Document Type: Article

References (21)

1. LoRusso PM, Anderson AB, Boerner SA, Averbuch SD. Making the investigational oncology pipeline more efficient and effective: are we headed in the right direction? Clin Cancer Res 2010;16: 5956-62.
2. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21:1431-9.
3. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84.
4. Kantarjian HM, Shah NP, Cortes JE, Baccarani M, Agarwal MB, Undurraga MS, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 2012;119:1123-9.
5. Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from national surgical adjuvant breast and bowel project protocol B-27. J Clin Oncol 2003;21:4165-74.
6. von Minckwitz G. Neoadjuvant chemotherapy in breast cancer-insights from the German experience. Breast Cancer 2012;19:282-8.
7. Esserman LJ, Berry DA, DeMichele A, Carey L, Davis SE, Buxton M, et al. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL-CALGB 150007/150012, ACRIN 6657. J Clin Oncol 2012;30:3242-9.
8. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007;13:2329-34.
9. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014;384:164-72.
10. Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010;375:377-84.
11. Piccart-Gebhart MJ, Holmes AP, Baselga J, Azambuja ED, Dueck AC, Viale G, et al. First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T!L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC) [abstract]. J Clin Oncol 2014;32:LBA4.
12. Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012;379:633-40.
13. Berry DA. In NeoALTTO & ALTTO Trials, Neoadjuvant Response Predicts Adjuvant. The Cancer Letter [Internet] 2014 Jul [cited 2014 July 11]; 40-28:[about 3 p.]. Available from: http://www.cancerletter.com/articles/20140711-2
14. Neratinib Graduates to I-SPY 3. Cancer Discovery 2014;4:624.
15. Mukhtar RA, Yau C, Rosen M, Tandon VJI-SPY 1 TRIAL and ACRIN 6657 Investigators Hylton N, et al. Clinically meaningful tumor reduction rates vary by prechemotherapy MRI phenotype and tumor subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Ann Surg Oncol 2013; 20:3823-30.
16. Mamounas EP, Anderson SJ, Dignam JJ, Bear HD, Julian TB, Geyer CE Jr, et al. Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. J Clin Oncol 2012;30: 3960-6.
17. Prowell TM, Pazdur R. Pathological Complete Response and Accelerated Drug Approval in Early Breast Cancer. N Engl J Med 2012;366: 2438-41.
18. Carey LA, Berry DA, Ollila D, Harris L, Krop IE, Weckstein D, et al. Clinical and translational results of CALGB 40601: a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer [abstract]. J Clin Oncol 2013;31 500.
19. Guarneri V, Frassoldati A, Bottini A, Cagossi K, Bisagni G, Sarti S, et al. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study. J Clin Oncol 2012;30:1989-95.
20. Robidoux A, Tang G, Rastogi P, Geyer CE, Azar CA, Atkins JN, et al. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. Lancet Oncol 2013;14:1183-92.
21. Hurvitz SA, Miller JM, Dichmann R, Perez AT, Patel R, Zehngebot LM, et al. Final analysis of a phase II 3-arm randomized trial of neoadjuvant trastuzumab or lapatinib or the combination of trastuzumab and lapatinib, followed by six cycles of docetaxel and carboplatin with trastuzumab and/or lapatinib in patients with HER2+ breast cancer (TRIO-US B07) [abstract]. Cancer Res 2013;73:S1-02.